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ABSTRACT: Cytochrome P450 3A4 (CYP3A4) is the major
human P450 responsible for the metabolism of carbamazepine
(CBZ). To explore the mechanisms of interactions of CYP3A4
with this anticonvulsive drug, we carried out multiple
molecular dynamics (MD) simulations, starting with the
complex of CYP3A4 manually docked with CBZ. On the basis
of these simulations, we engineered CYP3A4 mutants I369F,
I369L, A370V, and A370L, in which the productive binding
orientation was expected to be stabilized, thus leading to
increased turnover of CBZ to the 10,11-epoxide product. In
addition, we generated CYP3A4 mutant S119A as a control construct with putative destabilization of the productive binding
pose. Evaluation of the kinetics proﬁles of CBZ epoxidation demonstrate that CYP3A4-containing bacterial membranes
(bactosomes) as well as puriﬁed CYP3A4 (wild-type and mutants I369L/F) exhibit substrate inhibition in reconstituted systems.
In contrast, mutants S119A and A370V/L exhibit S-shaped proﬁles that are indicative of homotropic cooperativity. MD
simulations with two to four CBZ molecules provide evidence that the substrate-binding pocket of CYP3A4 can accommodate
more than one molecule of CBZ. Analysis of the kinetics proﬁles of CBZ metabolism with a model that combines the formalism
of the Hill equation with an allowance for substrate inhibition demonstrates that the mechanism of interactions of CBZ with
CYP3A4 involves multiple substrate-binding events (most likely three). Despite the retention of the multisite binding mechanism
in the mutants, functional manifestations reveal an exquisite sensitivity to even minor structural changes in the binding pocket
that are introduced by conservative substitutions such as I369F, I369L, and A370V.
Cytochrome P450 3A4 (CYP3A4) is the most abundantcytochrome P450 enzyme in the liver of most adult
humans.1 This enzyme, which metabolizes about 50% of drugs
on the market,2 is the main hepatic cytochrome P450 involved
in the metabolism of 5H-dibenzo[b,f ]azepine-5-carboxamide
(carbamazepine or CBZ). CBZ is a commonly prescribed
anticonvulsive drug; its major metabolite is carbamazepine-
10,11-epoxide (Figure 1).3,4
Numerous studies on in vitro CBZ epoxide formation that
include data from incubations with human liver microsomes
(HLM),4−8 recombinant enzyme expressed as microsomes
from insect cells,9,10 and reconstituted puriﬁed enzyme
preparations4,11,12 have been published: both hyperbolic and
sigmoidal dependencies of the reaction rate on the substrate
concentration have been observed. Diﬀering degrees of
homotropic cooperativity have been reported for HLM4,5,7,8
and microsomes from recombinant insect cells expressing
human CYP3A46,9 that exhibit sigmoidal proﬁles. Michaelis−
Menten kinetics4 as well as sigmoidal proﬁles7 have been
reported for puriﬁed and reconstituted CYP3A4. The apparent
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Figure 1. Structures of carbamazepine (left) and the major product of
its CYP3A4-dependent oxidation, carbamazepine-10,11-epoxide
(right).
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inconsistency among these reports demonstrates that epox-
idation of CBZ by CYP3A4 is very sensitive to both the
experimental conditions and the enzyme source. Such
inconsistencies in kinetics proﬁles have also been reported for
other substrates, such as amitriptyline, nifedipine, and
testosterone.13 CBZ qualiﬁes as a narrow therapeutic index
drug,14 of which the target for plasma concentration is 17−70
μM.7 Because failure to maintain the target plasma range may
cause toxic side eﬀects, continuous therapeutic monitoring is
desirable for optimal outcome of CBZ therapies. A potential
approach to continuous monitoring is to use biosensors
constructed from electrodes with immobilized P450 enzymes
that can detect drug substrates such as CBZ.15−17
In this study, we sought to explore the mechanism of
interaction of CYP3A4 with CBZ by engineering CYP3A4
variants with enhanced aﬃnity for CBZ and/or increased
epoxidation turnover. These studies were aimed at the
elaboration of a CYP3A4-based electrochemical biosensor
with improved capacity for determining CBZ concentration
in clinical samples. Our approach to the optimization of
CYP3A4 for CBZ binding encompasses explicit solvent
molecular dynamics (MD) simulations of the structure of the
CYP3A4 complex with CBZ in combination with site-speciﬁc
protein engineering to incorporate amino acid alterations in the
enzyme’s active site. On the basis of our MD simulations, we
designed four CYP3A4 mutants, each with putative stabilization
of the CBZ molecule in a predicted productive binding mode
that was aimed at increased aﬃnity for CBZ and increased
turnover of the epoxide product. We also constructed mutant
S119A, which putatively disrupts a critical hydrogen bond, as a
negative control with which we expected diminished turnover
of the epoxide product.
The chosen mutants were cloned, expressed, and puriﬁed,
and kinetics parameters of CYP3A4-dependent oxidation of
CBZ were studied in a soluble reconstituted system. Signiﬁcant
eﬀects of minor structural changes in the binding pocket of the
enzyme, caused by the substitutions S119A, I369L, I369F,
A370L, and A370V, were observed, demonstrating a profound
sensitivity of both the enzyme−substrate binding interactions
and the catalytic eﬃciency of CYP3A4. The observation of both
homotropic cooperativity and substrate inhibition in the
kinetics of CBZ epoxidation by wild-type and mutant
CYP3A4 suggests that the interactions of the enzyme with
the drug involve the binding to the enzyme of at least two, but
more likely three, CBZ molecules. This conclusion is supported
by multiple MD simulations that demonstrate the possible
accommodation of multiple CBZ molecules in the CYP3A4
binding pocket.
■ MATERIALS AND METHODS
Reagents. CBZ was purchased from Acros Organics
(Thermo Fisher Scientiﬁc, Waltham, MA, USA). L-α-
Phosphatidyl choline, L-α-phosphatidyl ethanolamine, and L-
α-phosphatidic acid were purchased from Avanti Polar Lipids
(Alabaster, AL, USA). 3-[(3-Cholamidopropyl)-dimethylam-
monio]-1-propansulfonate (CHAPS) was purchased from
Applichem GmbH (Darmstadt, Germany). HisPur Ni−NTA
beads were obtained from Thermo Fisher Scientiﬁc, and CM
macroprep ion-exchange support was obtained from Biorad
(Hercules, CA, USA). Escherichia coli HMS 174 (DE3) cells
were purchased from Merck, Darmstadt, Germany. Carbama-
zepine-10,11-epoxide, DEAE−sepharose fast-ﬂow ion-exchange
and adenosine 2′,5′-diphosphate agarose aﬃnity supports were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Primers
for recombinant DNA manipulations were obtained from
Microsynth (Balgach, Switzerland). 10-Methoxy-carbamazepine
was obtained from TLC PharmaChem (Vaughan, Ontario,
Canada). Bactosomes with a high reductase/CYP3A4 ratio
(Human CYP3A4R EasyCYP Bactosomes) were purchased
from CYPEX, Ltd. (Dundee, U.K.).
Computational Methods. Molecular Dynamics Simu-
lations. The simulations were carried out with the coordinates
extracted from the structure of the CYP3A4 complex with
metyrapone (Protein Data Bank (PDB): 1W0G).18 CBZ was
superimposed onto the bound structure of metyrapone, and
water molecules, ions, and the metyrapone molecule were
removed. Because of a lack of crystallographic density in the
ﬂexible segments, spurious N and C termini were neutralized
with acetyl groups at Asp270 and Ala289 and N-methyl-amide
groups at Glu262 and Ile276, whereas the natural termini were
considered charged. Missing side-chain atoms were added with
CHARMM.19 Parameters for CYP3A4 and HEME were
derived from the CHARMM27 force ﬁeld.20 The partial
charges of the Cys442 side-chain thiolate were set as developed
by Foloppe et al.21 CBZ was parametrized according to the
CHARMM general force ﬁeld22 and Paramchem.23,24
To determine the modes of binding of CBZ to CYP3A4, ﬁve
independent MD simulations of 50 ns each were carried out
with GROMACS (version 4.5.6).25 First, the CYP3A4−CBZ
complex was placed in a dodecahedral box, the size of which
was set with a margin of at least 13 Å from any atom of the
complex. The box was then ﬁlled with pre-equilibrated TIP3P
water molecules,26 and the system was neutralized with Na+
and Cl− ions at a concentration of 150 mM. Van der Waals and
short-range electrostatic interactions were calculated up to a
cutoﬀ of 10 Å. Long-range electrostatics were evaluated with
the particle mesh Ewald method,27 and periodic boundary
conditions were applied. All bonds involving hydrogen atoms
were constrained by the LINCS algorithm,28 and a 2 fs time
step was used. The temperature was kept constant at 310 K by
means of the velocity-rescaling algorithm implemented29 in
GROMACS, and the pressure was kept constant at 1 atm with a
Parinello Raman barostat.30,31 Mutations at the respective
residue indices were introduced by simple remodeling in
PyMOL.32 For the simulations with multiple copies of CBZ
bound, the starting positions were generated by manually
positioning two, three, or four molecules of CBZ in the active
site so that no steric clashes were introduced. All systems were
energy minimized for 10 000 steps of the conjugate gradient
algorithm before starting the MD. Subsequently, the system
was equilibrated in an NPT simulation for 1 ns. From the
resulting atomic positions, the production runs were started
with diﬀerent random seeds for the initial assignment of the
velocities.
Clustering. The WORDOM33 (version 0.22) implementa-
tion of the leader algorithm was used to cluster the snapshots
saved along the MD trajectories by a criterion that was based
on the root-mean-square deviation (RMSD) of the CBZ non-
hydrogen atoms. Only the last 10 ns of each 50 ns run were
used for clustering, i.e., the ﬁrst 40 ns of each run were
considered equilibration. First, the CYP3A4 Cα atoms were
used to overlap the structures of the coordinate sets in the ﬁve
10 ns segments with the X-ray structure. Starting from one of
the snapshots at 40 ns, which was taken as the ﬁrst cluster, the
leader algorithm proceeded iteratively by comparing each
snapshot with the representative of the previously deﬁned
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clusters. A snapshot was assigned to a cluster if the RMSD was
smaller than a threshold value of 2 Å. Simulations with two
CBZ molecules positioned in the active site were clustered with
a tree-based algorithm as provided in CAMPARI.34,35 RMSD-
based clustering over the entire 200 ns was carried out for each
of the two CBZ molecules separately with a threshold radius
(CRADIUS) of 2 Å, a tree height (BIRCHHEIGHT) of 16,
and a coarsest threshold (CMAXRAD) of 10 Å. CYP3A4 Cα
atoms were aligned before clustering. All ﬁgures were prepared
with the PyMOL package.32
Experimental Section. Recombinant DNA Manipula-
tions. Construct pSE3A4, expressing an N-terminally modiﬁed
human P450 3A4 with a tetra-histidine tag attached at the C-
terminus, was described previously.36 Site-directed mutagenesis
was carried out by means of PCR with the QuikChange Site-
Directed Mutagenesis Kit (Agilent Technologies, Stratagene
Products Division, La Jolla, CA, USA.).
Expression and Puriﬁcation of CYP3A4 and P450
Reductase. Freshly transformed E. coli Topp3 cells were
induced with 0.5 mM IPTG, and the CYP3A4 construct was
expressed for 48−72 h before cells were lysed by sonication;
expression levels were quantiﬁed by reduced CO binding.37
The enzyme was puriﬁed from solubilized membranes via
nickel-aﬃnity chromatography on Ni−NTA beads and anion-
exchange chromatography with CM macroprep ion-exchange
support as described previously.38,39 Recombinant NADPH
cytochrome P450 reductase (CYPOR) from rat liver was
expressed in E. coli Topp3 cells and was puriﬁed as described
previously.36 The purity of the enzymes was analyzed via SDS−
polyacrylamide gel electrophoresis and absorbance spectrosco-
py.
Absorbance Spectroscopy and Analysis of the Spectra.
The spectra were recorded at 28 °C with a Specord S 250 UV−
vis spectrophotometer equipped with a Peltier thermostat and a
stirring device (Analytik Jena, Jena, Germany). The concen-
trations and the spin state of CYP3A4 were quantiﬁed on the
basis of the approximation of the heme protein absorbance
spectra with a set of the prototype absorbance spectra of
CYP3A4’s (Fe3+) high-spin, low-spin, and P420 states.40 The
concentration of CYPOR was determined on the basis of the
prototypic spectrum of the pure enzyme with an extinction
coeﬃcient equal to 21.4 mM−1 cm−1 at 456 nm.41 In these
calculations, the linear least-squares approximations of the
spectra with combinations of the absorbance standards were
carried out with the SpectraLab software package.42
Reconstitution of Wild-Type Recombinant CYP3A4 and
Mutants. A functional mono-oxygenation system with CYP3A4
and CYPOR was reconstituted in a micellar system containing
phospholipids added as chloroform solutions of L-α-phospha-
tidyl choline, L-α-phosphatidyl ethanolamine, and L-α-phospha-
tidic acid mixed at a molar ratio of 1:2:0.6, respectively,39 as
well as 0.4% CHAPS. The pellet of phospholipids obtained
after removal of the solvent under a ﬂow of argon gas was then
resuspended in buﬀer A (100 mM HEPES, 150 mM KCl, 0.5
mM EDTA, and 1 mM DTT, containing 10% v/v glycerol, pH
7.4) to a ﬁnal concentration of 10 mg mL−1 (13.3 mM) by
vigorous shaking on a vortex mixer. The resulting suspension
was then homogenized by extrusion through a 200 nm pore-
size ﬁlter with an Avanti miniextruder (Avanti Polar Lipids,
Alabaster, AL, USA.). A mixture of CYP3A4 and CYPOR
containing 10 μM of each protein was then supplemented with
the 6.5 mM phospholipid suspension to an ﬁnal concentration
of 1.5 mM, and buﬀer A (1.5% CHAPS) was added to a ﬁnal
concentration of 0.4% CHAPS. The mixtures were incubated
overnight at 4 °C under continuous shaking in a table-top
thermomixer (Eppendorf, Hamburg, Germany). The reprodu-
cibility of the procedure with overnight incubation was
considerably better than that with 30 min incubation, and
subsequent activity measurements showed no decrease in
activity of the reconstituted enzyme after overnight compared
to that of after 30 min of shaking.
Kinetics Assay: Formation of Carbamazepine-10,11-
epoxide. Reactions were carried out at 37 °C in microreaction
tubes in a table-top shaker. The reconstituted enzymes were
diluted 20-fold into buﬀer (0.1 M HEPES, pH 7.4). The ﬁnal
concentrations of CYP3A4 and CYPOR were 0.5 μM, except
for the incubations involving CYP3A4 bactosomes, in which the
ﬁnal concentrations were 0.05 μM. The working concentration
of CHAPS was 0.02% (325 μM). CBZ was added from
methanol stock solutions for a ﬁnal methanol concentration of
1%, and addition of 20 μL of a 5× NADPH regeneration
system containing 25 mM glucose-6-phosphate (GSP), 5 U/
mL glucose-6-phosphate dehydrogenase (GSPDH), and 5 mM
NADP+ in 50 mM potassium phosphate buﬀer (pH 7.4)
brought the reaction volume to 100 μL and the ﬁnal
concentrations of the regeneration system components to 5
mM, 1 U/mL, and 1 mM, respectively. The reaction mixture
was buﬀered at pH 7.4 with 75 mM HEPES and 10 mM
potassium phosphate.
The linear ranges of product formation as a function of time
were determined for each mutant by taking aliquots of the
reaction mixture at 0, 5, 10, 15, 20, 25, and 30 min after
initiation of the reaction. For most of the mutants, we obtained
proﬁles for the increase in product concentration at the time
points larger than 20 min that were linear; the exceptions were
mutants S119A and I369F, for which the time dependence of
product formation was linear for only ca. 15 min.
Consequently, incubations were carried out for 20 min for
incubations with wild-type CYP3A4 and mutants I369L and
A370V/L and for 15 min with mutants S119A and I369F. All
incubations were conducted in triplicate. The enzymatic
reactions were stopped by adding an equal amount of ice-
cold methanol containing 20 μM of the internal standard 10-
methoxy-carbamazepine, followed by 1:1 dilution with
deionized water for a ﬁnal methanol concentration of 25%.
The samples were analyzed by reversed-phase HPLC on a
Ultimate 3000 system (Thermo Fisher Scientiﬁc, Reinach,
Switzerland) on a 150 mm × 4.5 mm diameter Gravity C18
column (Macherey-Nagel GmBH & Co. KG, Düren, Germany)
with 30:70 acetonitrile/water containing 0.1% formic acid as
the mobile phase.
The rates of reactions as a function of substrate
concentration were ﬁt to either the regular Hill equation or
the Hill equation complemented with an allowance for partial
substrate inhibition, as described in the Supporting Informa-
tion, by means of a combination of the Nelder−Mead and
Marquardt nonlinear regression algorithms, as implemented in
the SpectraLab software package.42
■ RESULTS
CBZ Epoxidation by CYP3A4-Containing Bactosomes.
In good agreement with previous studies of CYP3A4-
dependent metabolism of CBZ, we detected no product in
signiﬁcant amounts except for carbamazepine-10,11-epoxide.4
Upon examination of the substrate-concentration dependence
of the kinetics proﬁles, we extended the range of CBZ
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concentrations used in our analyses to 0−2000 μM, a
considerably larger concentration range than that reported in
previous studies.4−6,9 The kinetics proﬁle reveals moderate but
clearly pronounced substrate inhibition that becomes evident at
CBZ concentrations >700 μM (Figure 2). The ﬁt of the initial
parts of the titration curves ([CBZ] ≤ 1000 μM) with the Hill
equation (Figure 2, dashed line) is consistent with positive
cooperativity, with a Hill coeﬃcient (h) of 1.4 ± 0.4 (S50 = 162
± 4 μM, kcat = 1.9 ± 0.3 min
−1); this is in agreement with a
previous report in which CYP3A4-dependent epoxidation of
CBZ was characterized as exhibiting inherent homotropic
cooperativity with h = 1.4−1.7.7
However, the Hill equation ﬁts of the titration curves are
satisfactory only to a CBZ concentration of ca. 700 μM; at
higher concentrations, there is evident systematic deviation of
the experimental data from the equation curve (Figure 2, inset).
In an attempt to achieve an appropriate approximation of the
experimental data over the entire range of CBZ concentrations,
we ﬁt the data sets to the Michaelis−Menten equation adapted
for partial substrate inhibition, expressed as
α= +
+ +
V
k E S S K
K K S K S
[ ] [ ]( [ ] )
[ ]( [ ])S
cat 0 I
M I I (1)
where VS and kcat designate the reaction rate at substrate
concentration [S] and the apparent catalytic rate constant,
respectively. The Michaelis−Menten constant and the dis-
sociation constant of the enzyme complex with the inhibitory
substrate molecule are designated as KM and KI respectively,
and the coeﬃcient α represents the fraction of kcat that is
retained in the inhibitory complex when a second molecule of
substrate is bound. The derivation of this equation is described
in the Supporting Information.
As shown in Figure 2 (solid line), the experimental data sets
may be ﬁt to eq 1 (ρ2 ≥ 0.982) with no systematic deviations
over the entire range of CBZ concentrations studied (Figure 2,
inset). The parameters for ﬁtting eq 1, representing the
averages of the results obtained in three individual experiments,
are kcat = 3.1 ± 0.5 min
−1, KM = 140 ± 10 μM, KI = 1.6 ± 0.3
mM, and α = 0.21 ± 0.08. Therefore, the data obtained with
bactosomes are consistent with a model where the maximal rate
of CBZ metabolism is obtained by the complex of CYP3A4
with one substrate molecule, and the subsequent low-aﬃnity
binding of a second CBZ molecule to this complex results in an
ca. 5-fold decrease in the rate of CBZ metabolism. It appears
probable, therefore, that earlier reports of positive cooperativity
in CYP3A4-dependent CBZ metabolism should be questioned
because the titration curves thought to ﬁt the Hill equation
(Figure 2, dashed line) were recorded over a range of CBZ
concentrations too low to cause pronounced substrate
inhibition.
Probing the CBZ Binding Mode to CYP3A4 with MD
Simulations. According to the above analysis, we infer that the
complex of CYP3A4 with one substrate molecule in the
substrate-binding pocket may serve as an adequate initial model
of the catalytically competent complex of the enzyme with
CBZ. Thus, we selected a binary complex of CYP3A4 with one
CBZ molecule as the subject for initial MD simulations aimed
at eliciting the structure of the CBZ−CYP3A4 complex and the
orientation of the substrate molecule in the active site.
Figure 3b shows the time series of the backbone RMSD from
the X-ray structure of CYP3A4 (PDB: 1W0G),18 which reaches
a plateau between 2 and 3 Å after about 10 ns (equilibration
phase). We determined the binding modes of CBZ in ﬁve
independent MD runs of 50 ns each, where only the last 10 ns
of each run was evaluated. In the most populated, i.e., largest,
cluster of the CBZ poses, the heme iron is located within 5 Å of
the center of the bond between the carbon atoms 10 and 11
(C10,C11), which is compatible with the CYP3A4-catalyzed
epoxidation of CBZ (Figure 3a). It should be noted, however,
that the relevance of this binding mode to the actual
mechanism of interactions is diﬃcult to assess because it was
primarily sampled in only one of ﬁve MD runs. The CBZ
molecule that was initially superimposed at the position of the
removed metyrapone did not exit the CYP3A4 binding site in
any of the runs. On the basis of the binding mode of CBZ in
the largest cluster of poses deduced from MD simulations
(Figure 3a), we selected the amino acids S119, A370, and I369
as targets (Table S1). We suggested ﬁve single-point mutants
on the basis of the mean distances between the center of mass
(COM) of the respective residues and the COM of CBZ in this
Figure 2. Substrate dependence of the rate of formation of
carbamazepine-10,11-epoxide catalyzed by recombinant CYP3A4 in
bactosomes. Data points represent mean values from three individual
measurements, and the error bars show the respective standard
deviations. Results of ﬁtting to the Hill equation (dashed line) and to
eq 1 (solid line) are shown. The inset shows plots of the respective
residuals.
Figure 3. Results of MD simulations with the complex of wild-type
CYP3A4 with one molecule of CBZ. (a) A representative snapshot of
the most populated cluster. The residues selected for mutation (S119,
I369, and A370), CBZ, and the heme group are shown with stick
models in green, cyan, and magenta, respectively. The protein
backbone is shown in transparent gray. (b) Time series of the
RMSD from the crystal structure (PDB: 1W0G) of the protein
backbone after alignment of Cα carbons. The RMSD reaches a plateau
after about 20 ns in the ﬁve independent runs, each of which is plotted
with a diﬀerent color.
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cluster (Figure 3a). We predicted that mutants I369L, I369F,
A370V, and A370L would lead to improved steric comple-
mentarity, i.e., Van der Waals interactions, between CYP3A4
and the 5H-dibenzo[b,f ]azepine ring system of CBZ. Mutant
S119A was selected as a negative control and was designed to
disrupt the structural stability of the productive binding mode
by eliminating the hydrogen bond between the carbonyl oxygen
of CBZ and the S119 side-chain hydroxyl group.
Enzyme Expression, Puriﬁcation, and Reconstitutions.
On the basis of the results of the MD simulations, we elected to
probe the eﬀect of the mutations S119A, I369L, I369F, A370L,
and A370V on the metabolism of CBZ by CYP3A4. Expression
of all ﬁve constructs in E. coli provided stable P450 holoprotein,
which is in good agreement with earlier reports on the
expression and puriﬁcation of mutants S119A,43 A370V,44 and
I369F.45 The yields of expression obtained with all of these
mutants were generally somewhat lower than the yield of wild-
type CYP3A4.
As seen from the absorbance spectra of the puriﬁed enzymes
(Figure 4a), all ﬁve substitutions probed in this study caused a
notable increase in the amplitude of the heme protein
absorbance band at 396 nm relative to the amplitude of the
band at 417 nm. This is indicative of a displacement of the spin
equilibrium toward the ferric high-spin state. This displacement
is most pronounced in mutants I369F and S119A, where the
fraction of high-spin heme protein approaches 50%, in sharp
contrast to the spin state of wild-type CYP3A4, where the high-
spin fraction at 28 °C does not exceed 20% (Figure 4b).
Eﬀect of Mutations on CYP3A4-Dependent Epoxida-
tion of CBZ. In initial experiments, we assessed the turnover of
CBZ epoxidation in the reconstituted system with the puriﬁed
mutants and wild-type CYP3A4 (rCYP3A4) at apparent
subsaturating (0.1 mM) and saturating (1 mM) concentrations
of the substrate.
To analyze the eﬀects of these substitutions in more detail,
we evaluated broader kinetics proﬁles of wild-type CYP3A4 and
mutants in reconstituted system, increasing the range of CBZ
concentration studied up to 2 mM (Figure 5, Table 1).
Although the overall quality of the ﬁt of the titration curves
obtained with wild-type CYP3A4 to the Hill equation (Figure
5, dashed line, and Table 1, h = 2.0 ± 0.9, S50 = 300 ± 100 μM,
and kcat = 1.0 ± 0.3 min
−1) appears acceptable (ρ2 = 0.957),
systematic deviations of the experimental points (Figure 5a,
circles) suggest the presence of substrate inhibition at higher
concentrations, similar to that observed with the CYP3A4-
containing bactosomes. However, in the case of mutants I369F
and I369L, the substrate inhibition is much more evident than
with wild-type CYP3A4 (Figure 5a); mutants S119A, A370V,
and A370L show no visible signs of substrate inhibition (Figure
5b). In contrast, the S-shaped kinetics proﬁles obtained with
these mutants are indicative of a high degree of cooperativity.
To justify the apparent combination of the positive
cooperativity and substrate inhibition mechanisms observed
Figure 4. Eﬀect of mutations on the spin state of puriﬁed CYP3A4 proteins. (a) Absorbance spectra of wild-type CYP3A4 (blue) and its mutants:
I369F (red), I369L (green), S119A (light green), A370V (turquoise), and A370L (black). Spectra were normalized to correspond to a heme protein
concentration of 1 μM. The inset shows the Soret band region of the same spectra. (b) Respective fraction of the high spin state of these heme
proteins. Conditions: 100 mM HEPES, pH 7.4, 1 mM DTT, 10% v/v glycerol. The concentration of P450 was in the range of 1.5−2.5 μM.
Figure 5. Substrate dependence of the rate of formation of
carbamazepine-10,11-epoxide catalyzed by puriﬁed CYP3A4 and
mutants in the reconstituted system. Incubations were carried out
with 0.5 μM CYP3A4. Data points represent the mean values of three
individual measurements, and the error bars show the respective
standard deviations. Fits to the Hill equation (dashed line) and to eq 2
(solid line) are shown. (a) Plots obtained with wild-type CYP3A4
(circles) and the mutant enzymes I369F (squares) and I369L
(triangles). (b) Plots obtained with mutants S119A (circles), A370V
(squares), and A370L (triangles).
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in the mutants, we attempted to approximate the experimental
data with an equation representing a combination of the Hill
equation formalism with an allowance for substrate inhibition,
represented as
α= · · · + ·
· + · +
V
k E S K S
S K S K S
[ ] [ ] ( [ ])
[ ] ( [ ])
h
h hS
cat 0 I
50 I I (2)
The derivation of eq 2 is described in the Supporting
Information. The S50 term in eq 2 is deﬁned in a way similar
to that in the regular Hill equation: as the hth root of the
apparent dissociation constant of the catalytically competent
enzyme−substrate complex. Where h = 1, eq 2 reduces to eq 1,
and S50 is equivalent to KM.
The ﬁts of eq 2 to the data are shown in Figure 5 (solid
lines), and the respective parameters are summarized in Table
1. Equation 2 clearly provides a better model for ﬁtting data
sets obtained with wild-type CYP3A4, whether prepared as
bactosomes or as reconstituted systems, and with mutants
I369L and I369F. For the data obtained with the mutants, the
ﬁt to eq 2 is as good as that to eq 1. The values obtained for the
parameter α with mutants A370L and A370V are close to unity,
which suggests that the binding of additional substrate
molecules would not aﬀect the activity of the enzyme; thus,
we conclude that substrate inhibition is completely abolished in
these mutants.
Analysis of the kinetics parameters suggests that, over the ﬁve
mutations probed in this study, only the I369F substitution and,
especially, the A370V substitution cause considerable increases
in enzyme turnover with CBZ compared with wild-type (Table
1). In the case of I369F, the increase in the kcat value is
attenuated by enhanced substrate inhibition that is caused by a
decrease in the fraction of activity retained in the inhibitory
complex (α). However, for the A370V mutant, where substrate
inhibition is eliminated, the increase in the CBZ turnover is
substantial (Figure 5b, Table 1).
The clearly pronounced positive cooperativity in CBZ
metabolism observed with mutants A370V, A370L, and
S119A suggests that the formation of the catalytically
competent complex with CBZ in these mutants requires the
binding of at least two substrate molecules per molecule of the
enzyme. At the same time, in contrast to mutants A370V and
A370L, where substrate inhibition is eliminated, the ﬁt of the
data obtained with S119A to eq 2 indicates that the metabolism
of CBZ by this mutant is characterized by a combination of a
prominent positive cooperativity (h = 2.1 ± 0.3) with a
moderate degree of substrate inhibition (α = 0.5 ± 0.1); this
further suggests that the mechanism of interaction with CBZ
involves at least three separate substrate binding events.
MD Simulations of Two to Four CBZ Molecules in the
CYP3A4 Binding Pocket. On the basis of the analysis of the
kinetics proﬁles for CBZ metabolism, we concluded that
Table 1. Parameters of CYP3A4-Dependent Epoxidation of Carbamazepinea
Hill equationb Hill equation complemented with substrate inhibition (eq 2)
system kcat, min
−1 S50, mM h ρ
2 kcat, min
−1 S50, mM h Ki, mM α ρ
2
bactosomes 1.9 ± 0.3 0.16 ± 0.04 1.4 ± 0.4 0.979 2.9 ± 0.7 0.3 ± 0.2 1.06 ± 0.08 1.3 ± 0.8 0.3 ± 0.3 0.991
rCYP3A4 w/t 0.9 ± 0.3 0.3 ± 0.1 2.0 ± 0.9 0.957 1.4 ± 0.4 0.50 ± 0.04 1.4 ± 0.4 0.79 ± 0.04 0.6 ± 0.5 0.964
rCYP3A4
I369L
0.42 ± 0.06 0.14 ± 0.02 1.80 ± 0.10 0.884 0.8 ± 0.4 0.3 ± 0.2 1.4 ± 0.3 1.1 ± 0.5 0.2 ± 0.1 0.989
rCYP3A4
I369F
1.4 ± 0.2 0.20 ± 0.07 1.3 ± 0.5 0.932 3 ± 1 0.6 ± 0.4 1.2 ± 0.3 1.1 ± 0.6 0.2 ± 0.4 0.971
rCYP3A4
S119A
0.8 ± 0.1 0.61 ± 0.07 2.5 ± 0.4 0.985 1.2 ± 0.1 0.94 ± 0.08 2.1 ± 0.3 1.0 ± 0.2 0.5 ± 0.1 0.990
rCYP3A4
A370V
5 ± 1 1.0 ± 0.3 2.1 ± 0.9 0.991 4.6 ± 0.9 1.1 ± 0.3 1.9 ± 0.6 5 ± 8 0.96 ± 0.07 0.991
rCYP3A4
A370L
1.3 ± 0.4 0.6 ± 0.3 2.0 ± 0.6 0.993 1.2 ± 0.2 0.77 ± 0.07 1.7 ± 0.2 5 ± 9 1.4 ± 0.7 0.993
aThe values given in the table represent the averages of three individual measurements, and the values after ± show the conﬁdence intervals
calculated for p = 0.05. bIn cases with clearly pronounced substrate inhibition (CYP3A4 bactosomes, reconstituted systems with mutants I369L and
I369F), the ﬁtting to the conventional form of the Hill equation was carried out with the data subsets corresponding to a CBZ concentration range of
0−1 mM. The square correlation coeﬃcients given in the table correspond to the entire region of CBZ concentrations (0−2 mM) in all cases.
Figure 6. Results of MD simulations with the complex of two molecules of CBZ and (a) wild-type CYP3A4, (b) A370V, and (c) I369F. Each panel
shows two representatives that correspond to the most populated clusters obtained with each of the two CBZ molecules for clustering. Clustering of
the non-hydrogen atoms of the CBZ molecules was carried out upon structural alignment of all snapshots of the MD trajectories to the X-ray
structure via the Cα atoms of the α-helical residues of CYP3A4. Only in panel a are the orientations of the CBZ molecules diﬀerent, depending on
which of the two CBZ molecules was subjected to clustering, indicating that the sampling did not converge.
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changes in CBZ metabolism caused by the mutations at
positions 369, 370, and 119 cannot be accurately described by
simulations with a single CBZ molecule bound. Therefore, we
conducted MD simulations with two, three, or four CBZ
molecules positioned in the CYP3A4 binding pocket. Five MD
simulations each with two copies of CBZ in the active site were
carried out with wild-type CYP3A4 and mutants I369F and
A370V. Cluster analyses yielded nonidentical largest clusters for
both mutants and wild-type. The simulation times of 0.2 μs per
MD run, equal to a total sampling time of 1 μs for each of the
three CYP3A4 variants, were intended to achieve convergent
data. Importantly, similar to the single-CBZ simulations, the
clusters obtained stem mainly from only one of the ﬁve runs,
which is indicative of a lack of convergence. The largest clusters
for each of wild-type CYP3A4 and mutants A370V and I369F
are shown in Figure 6. Only for the A370V mutant (Figure 6b)
is the binding mode, i.e., the position and orientation, of the
CBZ closest to the heme essentially identical to that of the
most populated cluster in the single-CBZ wild-type run with
the C10−C11 bond close to the heme iron (Figure 3a).
Interestingly, the hydrogen bond observed between S119 and
the carbonyl oxygen of one CBZ molecule is retained in all
panels in Figure 6, which further supports our hypothesis that
S119 plays an important role in substrate binding.
Partial dissociation of a single CBZ molecule was observed in
one of the multiple-CBZ MD simulations (Figures 7 and S1).
Analysis of the unbinding pathway reveals that the CBZ
molecule moves to the periphery of CYP3A4 through the F′-
helix β-sheet-1 putative substrate-binding channel predicted by
Williams et al.18 To assess the ability of CYP3A4 to
accommodate more than two CBZ molecules, we carried out
ﬁve independent MD runs of 100 ns each with wild-type
CYP3A4 plus three or four CBZ molecules (Figure S1). No
dissociation events were observed, and the distance of the CBZ
molecule furthest from the heme iron was never larger than 18
Å. These results indicate that the CYP3A4 binding pocket is
large enough to accommodate up to four CBZ molecules and
that the A370V and I369F mutations considerably aﬀect the
mobility of CBZ molecules bound in the binding pocket.
■ DISCUSSION
The present study represents the ﬁrst attempt to employ MD
simulations to produce CYP3A4 mutants with enhanced
activity of epoxidation of carbamazepine combined with
subsequent in vitro examination of the impact of the mutations
on kinetics parameters. Our initial studies of the kinetics of
CBZ epoxidation by CYP3A4-containing bactosomes reveal
pronounced substrate inhibition, leading us to suggest that the
apparent positive cooperativity reported in earlier studies of
CBZ metabolism might be due to the limited range of substrate
concentrations examined. We demonstrate that the kinetics
proﬁles obtained with bactosomes adequately approximate the
Michaelis−Menten equation complemented with an allowance
for partial substrate inhibition (eq 1). The complex of CYP3A4
with one substrate molecule bound in the substrate-binding
pocket (Figure 3) may be taken as a reasonable model of the
catalytically competent complex.
In the MD simulations carried out with a single CBZ
molecule, the most populated cluster displays a productive CBZ
binding mode that is compatible with the epoxidation reaction.
The distance between the COM of CBZ carbon atoms 10 and
11 to the heme iron is less than 5 Å. On the basis of the analysis
of the structure in this cluster, we identiﬁed CYP3A4 mutations
(I369L, I369F, A370V, and A370L) that could lead to
improved steric complementarity via Van der Waals inter-
actions of the enzyme with the three-ringed 5H-dibenzo-
[b,f ]azepine system of CBZ. The S119A mutation was designed
to abolish the hydrogen bond to the carboxyl function of CBZ
to decrease the stability of the binding mode and, thus, the
overall binding aﬃnity.
Although the approach that was based on MD simulations
with one CBZ molecule was successful in the case of mutants
I369F and A370V, where the maximal rate of CBZ turnover is
considerably increased, examination of the kinetics proﬁles of
CBZ metabolism with the full series of mutants reveals certain
limitations of this simpliﬁed model. We can best approximate
the kinetics proﬁles obtained in vitro with wild-type CYP3A4 or
mutants by means of a model that combines the positive
cooperativity mechanism with an allowance for partial substrate
inhibition (eq 2). According to our analysis with this model,
marginal cooperativity (h = 1.2−1.4) is exhibited by wild-type
CYP3A4 and mutants I369L and I369F, whereas the
cooperativity is more clearly pronounced (h = 1.7−2.1) in
mutants S119A, A370V, and A370L. Substrate inhibition is
quite modest in wild-type CYP3A4 and the S119A mutant (α ≈
0.5) and eliminated in mutants A370V and A370L (α ≈ 1), but
it is considerably enhanced in mutants I369L and I369F (α ≈
0.2). The complex mix of positive cooperativity and substrate
inhibition in CBZ metabolism are consistent with the results of
Egnell and co-workers,7 who compared the kinetics proﬁles for
CBZ epoxidation by HLM to those obtained with puriﬁed
CYP3A4 in a reconstituted system and demonstrated that
although data obtained with HLM are consistent with a two-site
model where binding of the ﬁrst CBZ molecule increases the
Figure 7. Pathway of egress from the heme pocket for one of the two
bound CBZ molecules from wild-type CYP3A4 to a distance >20 Å
from the heme iron. (a) Structure of CYP3A4 showing the positions of
the CBZ molecule during its dissociation. The initial position of the
CBZ molecule is highlighted in green and the positions after 50, 100,
150, and 200 ns are shown in cyan, magenta, yellow, and maroon,
respectively. The second CBZ molecule is not shown. (b) Time series
of the COM distance between CBZ C10,C11 and the heme iron. The
distances of the bound CBZ molecule are shown in black, and the
distances of the unbinding CBZ molecule are shown in colors
corresponding to those used in panel a. The green arrow indicates the
starting position of the molecule. (c) Surface circumscribed by the
central nitrogen atom of the dissociating CBZ molecule over the
course of a single 200 ns simulation. The protein backbone from the
ﬁrst snapshot of the simulation is shown in white and does not account
for changes during the simulation. The arrows indicate the general
direction of the movement of the CBZ molecule.
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enzyme aﬃnity for binding of a second substrate molecule the
reconstituted system instead exhibits substrate inhibition.7
On the basis of our ﬁndings, we suggest that CYP3A4−CBZ
interaction is best explained with a model that involves binding
of three or more CBZ molecules in the active site. MD
simulations of the complex of CYP3A4 with two to four CBZ
molecules provide strong support for this suggestion; no
complete egress of substrate was observed in ﬁve MD
simulations involving three or four CBZ molecules. In the
simulations where two molecules of CBZ are bound to wild-
type CYP3A4 or mutants I369F or A370V (Figure 6), the most
populated binding mode of the single-copy simulations of CBZ
was observed only for A370V: in this case, one of the two CBZ
molecules is bound in a putative catalytic pose. The ﬁnding that
this pose appears to be stabilized by the second CBZ molecule
provides a plausible explanation for homotropic cooperativity in
CBZ epoxidation. Indeed, the A370V mutant is the only one of
the three enzyme variants probed with simulations that exhibits
prominent homotropic cooperativity (Figure 5, Table 1).
However, given the limited sampling in the simulations, we
caution that this observation may be coincidental.
In the 15 simulations of 2 CBZ molecules in the active site of
CYP3A4 (5 simulations each with wild-type, A370V, and
I369F), only one partial egress of substrate was observed: the
case of wild-type CYP3A4 (Figure 7). We compared the
cumulative volume of the dissociation trajectory of the CBZ
undergoing partial dissociation via the sampled volume of the
COM of C10/11 (Figure 7c) to the position of the substrate
access channel predicted by Williams et al. on the basis of the
X-ray structure (PDB: 1W0G) of CYP3A418 and found that the
volumes largely match; hence, our simulation supports the
geometry of the substrate- and solvent-accessible binding
pocket of CYP3A4 previously proposed.
Although a multisite binding mechanism in mutants is
retained, the enzyme is exquisitely sensitive to the minor
structural changes in the binding pocket introduced by the
point mutations S119A, I369F, I369L, A370L, and A370V. The
observation of the hydrogen bond between the CBZ molecule
adjacent to the heme and the S119 residue (Figure 6) provides
a clue to the eﬀects of the S119A substitution (Figure 4, Figure
5, Table 1). Importantly, this bond is found in the structures of
all simulated variants (wild-type, A370V, and I369F). The
absence of the stabilizing hydrogen bond in the S119A mutant
may explain the reduced aﬃnity of this mutant for CBZ.
Further, enhancement of homotropic cooperativity in CBZ
epoxidation by this mutation reveals an increased role for the
binding of a second substrate molecule in stabilizing the
catalytically competent complex. These results also support that
residue S119 plays a key role in substrate binding in
CYP3A4,44,46−50 in agreement with a recent study in which it
was shown that the association of CYP3A4 with ritonavir
analogues, which do not engage in hydrogen bonding to S119,
is facilitated by polar interactions mediated by the S119
residue.50
Possible eﬀects of the mutations on the structure of CYP3A4
are illustrated in Figure 8, which shows the largest clusters
obtained in simulations with two CBZ molecules of wild-type
CYP3A4 and mutants I369F and A370V compared to the X-ray
crystal structure of CYP3A4 with metyrapone (PDB: 1W0G).18
The π−π stacking interactions between residues F316 and F367
that are also found in most X-ray structures are likely to be
structurally important. The residues I369 and A370 reside in
the 1.4 K β loop (residues 368−372) that connects the α helix
K (violet) with the subsequent β strand (blue) and adjoins the
active site in Van der Waals contact to the α helix I (green).
The structural changes upon substitution of phenylalanine at
I369 are apparently important for the increased substrate
inhibition observed in the I369F mutant (Figure 5, Table 1).
The substitution at I369 with phenylalanine (or leucine) is
likely to aﬀect hydrophobic interactions in the active site,
thereby promoting inhibitory substrate-binding and/or steric or
conformational eﬀects. The I369F substitution may reduce the
volume of the active site and concomitantly restrict access to
the heme (Figure 8c). The bulky phenylalanine residue 369 in
the vicinity of the heme is likely to destabilize the ligation of the
water molecule in the low-spin P450 state and to be the source
of the observed increase in the proportion of high-spin P450 in
the substrate-free I369F mutant (Figure 4). The I369F
substitution may reduce the empty space between the 1.4 K/
β loop and helix I that face each other in the active site. An
analysis of the trajectories of residues F304 and 369 in the MD
simulations (Figure S2) reveals a decrease of the mean distance
between the side chains of these residues (blue dashes in Figure
8b−d) from ∼11.6 Å in wild-type CYP3A4 (ΔSC(WT), Figures
8b and S2) to ∼8.0 Å in I369F (ΔSC(I369F), Figures 8c and S2)
Figure 8. Comparison of the X-ray structure of CYP3A4 (PDB:
1W0G) with the simulated structure cluster representatives. (a) Active
site of CYP3A4 structure with metyrapone (light blue) bound.18 (b−
d) Cluster representatives of MD simulations of (b) CYP3A4 wild-
type and mutants (c) I369F and (d) A370V with two CBZ molecules
(marine blue). Residues F316 and F367 (orange) apparently engage in
π−π stacking interactions. The 1.4 K/β loop (consisting of residues
368−372 (PIAMR) that join the K helix (violet) to the sequential β
sheet (blue)) makes Van der Waals contacts with the long I helix
(green). Mutated residues are shown in yellow. Note: in panel c, the
bulky phenylalanine in the I369F mutant projects into the active site,
reducing the accessibility of the heme. Over the length of one
simulation of the I369F mutant, the I helix exhibits a kink (black
arrow) around residue F304 that additionally restricts access to the
active site because of a dramatic decrease in the distance between the
side-chains of F304 and residue 369 (blue dashes). The average
distances over the total simulation time are (b) ΔSC(WT) ≈ 11.6 Å in
wild-type CYP3A4, (c) ΔSC(I369F) ≈ 8.0 Å in the I369F mutant, and
(d) ΔSC(A370V) ≈ 13.0 Å in the A370V mutant.
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on average over the total simulation; the corresponding
distance in the A370V mutant was ∼13.0 Å (ΔSC(A370V),
Figures 8d and S2). The formation of a kink in the helix near
the F304 residue (Figure 8c, black arrow) may further restrict
access to the active site in the I369F mutant: this conforma-
tional change was, however, seen in only one out of ﬁve
simulations. Furthermore, although not revealed in the
simulations, a direct interaction of the I369F phenylalanine
with residue F304 may be possible and contribute to the
changes in the kinetics observed with this mutant. In the I369L
mutant, the side-chain γ-methyl groups of leucine may more
closely interact with the T309 side chain to move the 1.4 K/β
loop and to induce a similar conformational change in helix I as
seen in the simulation of the I369F mutant. A direct eﬀect of
the leucine on the accessibility to the heme may also be
plausible.
Stabilization of substrate binding by the additional phenyl-
alanine residue near the heme moiety in the I369F mutant via
stacking interactions of the aromatic rings may contribute to
the high rate of CBZ turnover observed with this mutant at low
CBZ concentrations. At higher CBZ concentrations, the
presence of several CBZ molecules stacked on top of each
other above the heme may prevent dissociation of product and
be responsible for the observed substrate inhibition (Table 1).
Elimination of substrate inhibition in mutants A370V and
A370L (Figure 5, Table 1) is associated with a signiﬁcant
increase in the S50 value for these mutants as compared to that
of wild-type, and the decreased aﬃnity for CBZ provides
further support for the importance of the K/β-loop region for
CBZ binding. It seems plausible that the steric clashes between
the larger aliphatic side chains of the valine and leucine of these
mutants and the metabolized or stabilizing CBZ molecule may
destabilize the substrate stacking, which is hypothesized to be
responsible for substrate inhibition.
The observation that the mutants with higher aﬃnities for
CBZ display more pronounced substrate inhibition provides
additional support for the above hypothesis that the mechanism
of substrate inhibition is due to the binding of additional CBZ
molecules that impede the egress of product. In contrast, the
ﬁnding that the mutants with lower aﬃnities for CBZ exhibit
homotropic cooperativity is consistent with the stabilization of
the catalytically competent enzyme−substrate complex upon
binding of a second CBZ. Whether these correlations are
speciﬁc to metabolism of CBZ or represent a general
characteristic of CYP3A4-catalyzed reactions requires further
experimentation.
In view of our original goal to generate CYP3A4 variants for
use in biosensors capable of detecting CBZ, one may argue that
the A370V variant is the best candidate because it exhibits the
highest maximal rate of CBZ turnover of all the probed enzyme
variants. However, taking into account that the target
therapeutic concentrations of CBZ in blood plasma are limited
to the range of 17 to 70 μM,7 we may conclude that the
decreased aﬃnity of A370V for CBZ (S50 = 1.1 mM)
undermines its practical utility. In our view, the most promising
enzyme variant for practical use is I369F, where the rate of CBZ
turnover is increased 2-fold and the S50 value obtained with the
use of eq 2 remains unaﬀected (Table 1). However, it should be
taken into account that the rate of substrate turnover and the
utilization of the reducing equivalents by the enzyme do not
necessarily obey a strict proportionality. Baas et al. showed that
the consumption of NADPH as a source of reducing
equivalents for CYP3A4 reaches its maximum at substrate
concentrations that are subsaturating for the enzymatic
turnover of testosterone.51 Furthermore, the actual relation-
ships between the faradaic current to the electrodes and the
enzyme turnover may diﬀer between the mutants. Therefore,
further assessment of the potential utility of the generated
CYP3A4 variants for the use in CBZ sensors requires
investigations with the enzyme immobilized on the electrode
surface.
Determination of the crystal structures of the CYP3A4
variants investigated in this study, such as I369F and S119A,
would be expected to yield important insights regarding the
relevance of structural aspects to mechanisms of substrate
inhibition and homotropic cooperativity in CYP3A4. In spite of
the structural plasticity of CYP3A4,47,52 we have been able to
use MD simulations to identify plausible productive and
nonproductive binding modes for one or more substrate
molecules in the substrate-binding pocket of the enzyme. In
particular, the combination of MD simulations and pose
clustering to guide site-directed mutagenesis has resulted in the
design of enzyme variants that exhibit altered functional
properties, such as homotropic cooperativity, substrate
inhibition, and substrate aﬃnities, in vitro. This approach may
prove to be generally applicable to other enzyme−substrate
pairs as a means to probe binding interactions and mechanisms
and to modulate functionality.
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